EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Crossing the ADC inflection points: what separates clinical success from failure

Antoine Yver

Bioconjugate Insights · 23.02.2026 · 1 (1) · 41–48

DOI: 10.18609/bci.2026.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Insights, online erschienen am 23.02.2026. Verfasst von Antoine Yver. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

“Drug development is not a race to be first; it is a race to win. History is full of examples where being first did not matter, but being right did.” Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Antoine Yver, Board Chair, Ona Therapeutics, with more than three and a half decades of experience shaping global cancer drug development. In this conversation, they explore what determines whether an ADC successfully crosses the critical threshold and how teams should rethink dose finding, toxicity, and what it truly takes to set a program up for long-term success in the clinic.

Zitieren

APA

Yver, A. (2026). Crossing the ADC inflection points: what separates clinical success from failure. Bioconjugate Insights, 1(1), 41–48. https://doi.org/10.18609/bci.2026.007

Vancouver

Yver A. Crossing the ADC inflection points: what separates clinical success from failure. Bioconjugate Insights. 2026;1(1):41–48. doi:10.18609/bci.2026.007

BibTeX
@article{Yver2026,
  author = {Yver, Antoine},
  title = {Crossing the ADC inflection points: what separates clinical success from failure},
  journal = {Bioconjugate Insights},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {41–48},
  doi = {10.18609/bci.2026.007}
}
Kostenlos starten →